ExodusPoint Capital Management LP Buys Shares of 16,198 Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)

ExodusPoint Capital Management LP bought a new stake in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE – Get Rating) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 16,198 shares of the biotechnology company’s stock, valued at approximately $109,000.

Other large investors also recently added to or reduced their stakes in the company. International Biotechnology Trust PLC acquired a new position in Concert Pharmaceuticals during the 2nd quarter valued at about $620,000. UBS Group AG lifted its position in Concert Pharmaceuticals by 42.6% during the 3rd quarter. UBS Group AG now owns 13,861 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 4,142 shares during the period. Virtu Financial LLC acquired a new position in Concert Pharmaceuticals during the 1st quarter valued at about $47,000. Jane Street Group LLC acquired a new position in Concert Pharmaceuticals during the 1st quarter valued at about $56,000. Finally, SG Americas Securities LLC acquired a new position in Concert Pharmaceuticals during the 3rd quarter valued at about $114,000. 70.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on CNCE shares. StockNews.com upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Jefferies Financial Group downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 19th. Jonestrading reiterated a “hold” rating on shares of Concert Pharmaceuticals in a research report on Friday, January 20th. Truist Financial downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 19th. Finally, JMP Securities downgraded shares of Concert Pharmaceuticals to a “market perform” rating in a research report on Thursday, January 19th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $21.00.

Insiders Place Their Bets

In other Concert Pharmaceuticals news, CEO Roger D. Tung sold 9,240 shares of the firm’s stock in a transaction that occurred on Friday, January 6th. The shares were sold at an average price of $7.24, for a total transaction of $66,897.60. Following the sale, the chief executive officer now directly owns 971,018 shares in the company, valued at approximately $7,030,170.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Nancy Stuart sold 6,048 shares of the firm’s stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $8.33, for a total transaction of $50,379.84. Following the completion of the transaction, the chief operating officer now directly owns 262,596 shares of the company’s stock, valued at approximately $2,187,424.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger D. Tung sold 9,240 shares of the firm’s stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $7.24, for a total transaction of $66,897.60. Following the transaction, the chief executive officer now directly owns 971,018 shares of the company’s stock, valued at $7,030,170.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,636 shares of company stock worth $350,763. Company insiders own 11.33% of the company’s stock.

Concert Pharmaceuticals Stock Performance

Shares of CNCE stock opened at $8.37 on Friday. The company has a market capitalization of $401.26 million, a P/E ratio of -2.61 and a beta of 0.52. The company’s 50 day moving average price is $7.63 and its two-hundred day moving average price is $6.41. Concert Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $8.55.

Concert Pharmaceuticals Company Profile

(Get Rating)

Concert Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.